BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Prognosis
41 results:

  • 1. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
    Wang WN; Liu XT; Liang YM
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
    [No Abstract]    [Full Text] [Related]  

  • 2. Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma.
    Tian X; Zhu S; Liu W; Wu X; Wei G; Zhang J; Anwaier A; Chen C; Ye S; Che X; Xu W; Qu Y; Zhang H; Ye D
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17451-17466. PubMed ID: 37889309
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
    He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Cuproptosis-Related Ferroptosis genes for Predicting prognosis in kidney renal clear cell carcinoma.
    Luo G; Wang L; Zheng Z; Gao B; Lei C
    Eur J Med Res; 2023 May; 28(1):176. PubMed ID: 37189176
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Comprehensive analyses of cuproptosis-related gene cdkn2a on prognosis and immunologic therapy in human tumors.
    Zhang D; Wang T; Zhou Y; Zhang X
    Medicine (Baltimore); 2023 Apr; 102(14):e33468. PubMed ID: 37026918
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.
    Golkaram M; Kuo F; Gupta S; Carlo MI; Salmans ML; Vijayaraghavan R; Tang C; Makarov V; Rappold P; Blum KA; Zhao C; Mehio R; Zhang S; Godsey J; Pawlowski T; DiNatale RG; Morris LGT; Durack J; Russo P; Kotecha RR; Coleman J; Chen YB; Reuter VE; Motzer RJ; Voss MH; Liu L; Reznik E; Chan TA; Hakimi AA
    Genome Med; 2022 Dec; 14(1):143. PubMed ID: 36536472
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Genomic alteration of MTAP/cdkn2a predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma.
    Xu W; Anwaier A; Liu W; Wei G; Su J; Tian X; Xia J; Qu Y; Zhao J; Zhang H; Ye D
    Front Immunol; 2022; 13():953721. PubMed ID: 35979371
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Bui TO; Dao VT; Nguyen VT; Feugeas JP; Pamoukdjian F; Bousquet G
    Eur Urol; 2022 Apr; 81(4):349-361. PubMed ID: 34991918
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation-dependent probe amplification.
    Yoshikawa Y; Yamada Y; Emi M; Atanesyan L; Smout J; de Groot K; Savola S; Nakanishi-Shinkai Y; Kanematsu A; Nojima M; Ohmuraya M; Hashimoto-Tamaoki T; Yamamoto S
    Cancer Sci; 2022 Jan; 113(1):297-307. PubMed ID: 34687579
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Brain natriuretic peptide and cardiac troponin I for prediction of the prognosis in cancer patients with sepsis.
    Yang Y; Leng J; Tian X; Wang H; Hao C
    BMC Anesthesiol; 2021 May; 21(1):159. PubMed ID: 34030651
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Mutant cdkn2a regulates p16/p14 expression by alternative splicing in renal cell carcinoma metastasis.
    Sun Q; Chen S; Hou Y; Wen X; Teng X; Zhang H; Lai C; Lai M
    Pathol Res Pract; 2021 Jul; 223():153453. PubMed ID: 34022680
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.
    Diez-Calzadilla NA; Noguera Salvá R; Soriano Sarrió P; Martínez-Jabaloyas JM
    Cancer Treat Res Commun; 2021; 27():100374. PubMed ID: 33932757
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
    Trpkov K; Hes O; Williamson SR; Adeniran AJ; Agaimy A; Alaghehbandan R; Amin MB; Argani P; Chen YB; Cheng L; Epstein JI; Cheville JC; Comperat E; da Cunha IW; Gordetsky JB; Gupta S; He H; Hirsch MS; Humphrey PA; Kapur P; Kojima F; Lopez JI; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Menon S; Netto GJ; Przybycin CG; Rao P; Rao Q; Reuter VE; Saleeb RM; Shah RB; Smith SC; Tickoo S; Tretiakova MS; True L; Verkarre V; Wobker SE; Zhou M; Gill AJ
    Mod Pathol; 2021 Jul; 34(7):1392-1424. PubMed ID: 33664427
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Adherent Perinephric Fat: a prognosis and influence of perioperative results of organ-sparing procedures in localized kidney parenchyma tumors].
    Syrota AE; Rapoport LM; Bezrukov EA; Tsarichenko DG; Syrota ES; Vovdenko SV; Alyaev YG
    Urologiia; 2020 Jun; (3):98-102. PubMed ID: 32597595
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Ara-c induces cell cycle G1/S arrest by inducing upregulation of the ink4 family gene or directly inhibiting the formation of the cell cycle-dependent complex CDK4/cyclin D1.
    Sun F; Li N; Tong X; Zeng J; He S; Gai T; Bai Y; Liu L; Lu K; Shen J; Han M; Lu C; Dai F
    Cell Cycle; 2019 Sep; 18(18):2293-2306. PubMed ID: 31322047
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
    Wang Y; Zhao W; Liu X; Guan G; Zhuang M
    J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The genomics of renal cell carcinoma and its role in renal mass biopsy.
    Salami SS; George AK; Udager AM
    Curr Opin Urol; 2018 Jul; 28(4):383-391. PubMed ID: 29708949
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immunohistochemical study of cyclin A and p16 expression in patients with renal cell carcinoma.
    Latic D; Radojevic-Skodric S; Nikolic S; Prvanovic M; Lazic M; Dzamic Z; Bogdanovic L; Radunovic M; Vukovic M
    J BUON; 2017; 22(5):1322-1327. PubMed ID: 29135120
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Correlation of RGS4 and p16 expressions with pediatric nephroblastoma and its significance on prognosis.
    Liu XX; Gong HF; Zhao XX
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4577-4583. PubMed ID: 29131258
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Commentary on: "Comprehensive molecular characterization of papillary renal-cell carcinoma." Cancer Genome Atlas Research Network.: N Engl J Med. 2016 Jan 14;374(2):135-45.
    Lee BH
    Urol Oncol; 2017 Sep; 35(9):578-579. PubMed ID: 28780132
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.